StemCell Therapy

Known for his rock 'n' roll antics and attitude, Liam Gallagher may need to take better care of his health as he enters middle age. It was only last year when the star revealed he has arthritis in his hip.

Named as William John Paul Gallagher at birth, the 48-year-old has matured in the spotlight.

Twice divorced, and the father of four children, Liam did a candid interview with Q Magazine in June 2019.

It was there he stated he suffers from arthritis in his hip - a painful inflammatory condition.

Dad to Molly (22), Lennon (21), Gene (19) and Gemma (seven), Liam is still keen to maintain his rock 'n' roll image.

Due to his arthritis, he has developed calf pain he's been seeking treatment for.

Speaking about his acupuncture treatment, he said: "This geezer is mega, he doesnt f**k about.

"He gets the needles and whacks them in. He sorts it but it keeps coming back. Acupuncture is alright, at least its needles."

READ MORE:Coronavirus vaccine roll out priority: List outlines who in britain will get jab first

Another charity, Versus Arthritis, said: "Its common to have aches and pains in your muscles and joints from time to time.

"This may especially be true if you take part in unusual or strenuous physical activities."

This can make it difficult to identify the warning signs of arthritis, but the charity makes it crystal clear on how you can spot the disease early.

"If you have swelling or stiffness that you cant explain and that doesn't go away in a few days, or if it becomes painful to touch your joints, you should see a doctor," it advised.

If you're diagnosed with arthritis, you may be offered medical treatments.

In addition to medication, Versus Arthritis encourage sufferers to exercise.

"Exercise can make symptoms such as pain and swelling better," it certified.

Low-impact exercises are typically recommended, such as cycling, brisk walking, yoga, T'ai Chi and pilates.

Be aware that "some discomfort and pain" is expected when you exercise, but it "should calm down a few minutes after you finish".

However, "it's important to not overdo it" added the charity. "The key is to start off gently and to gradually increase the amount you do."

Physical activity also helps you to maintain a healthy weight (or achieve one), which can put less pressure on the joints.

This in turn can help relieve the painful effects of arthritis.

See the original post here:
Liam Gallagher health: Rockstar has arthritis in his hip- what is this condition? - Express

A recent grant to UAB researchers from a national organization will yield insight into telehealth and potentially increase patient access to rheumatic care.

Jeffrey Curtis, M.D.The need for virtual health care options has significantly increased because of the COVID-19 pandemic. UAB researchers and collaborators have received a two-year, $400,000 grant from the American College of Rheumatologys Rheumatology Research Foundation to support telehealth-delivered health care.

Jeffrey Curtis, M.D., professor of medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham, will use this grant to support the project Telehealth-delivered Healthcare to Improve Care THRIVE in community-practice rheumatology. The projects collaborators include Cedars-Sinai Medical Center, CreakyJoints, a digital arthritis community for patients and caregivers worldwide, and its ArthritisPower research registry. The THRIVE projects primary investigator, Swamy Venuturupalli, M.D., is the recipient of this years ACRs Norman B. Gaylis, M.D., Clinical Research Award, and is slated to begin in January of 2021.

This grant is an exciting opportunity to identify and build best-in-class approaches to telehealth and to test specific strategies to assess patients with inflammatory arthritis, particularly rheumatoid arthritis, Curtis said. Clinical trials and routine patient care have been severely hampered by COVID-19-related perturbations in care delivery. We will scope and validate methods for disease activity assessment using telehealth-related technology, coupled with remote patient monitoring capabilities, including digitally captured, patient-reported outcome data.

The THRIVE project seeks to define, solidify and incorporate the best practices in telehealth rheumatology, disseminating these tools to community rheumatologists everywhere through a variety of channels.

The ultimate goal of this project is to increase patient access to care, expand the impact of rheumatology especially for those marginalized or most at risk by the COVID-19 pandemic and enable and improve the value of care provided by rheumatology providers in community settings through telehealth.

We are excited about the partnership between academia, community practitioners and arthritis patient communities, in what we expect to be a model paradigm for collaborative, practice-based research now and into the future, Curtis said.

Read the rest here:
Rheumatology Research Foundation grant allows for advancement in telehealth - The Mix

This report on Psoriatic Arthritis Treatment market, published by DataIntelo, is an in-depth analysis that studies crucial aspects of the market, which will assist clients to make right decision about their business investment plans and strategies. The market report entails a detailed information regarding the key segments and sub-segmentations including the product types, applications, and regions by examining the emerging market size, performance, and scope of each segment of the Psoriatic Arthritis Treatment.

Keeping 2019 as the base year, the report evaluates the extensive data available of the Global Psoriatic Arthritis Treatment Market for the historical period, 2015-2018 and assess the market trend for the forecast period from 2020 to 2026. With an aim to supply a robust assessment of the market, the report offers vital insights on industry growth opportunities and development, drivers and restrains for the Psoriatic Arthritis Treatment market with focusing on consumers behavior and industrial trend for the prior years as well as the base year.

Request a sample before buying this report @ https://dataintelo.com/request-sample/?reportId=118149

One key aspect of the report is that it provides an extensive study on the impact of COVID-19 pandemic on the global market and explains how it would affect the future business operations of the industry. In short, DataIntelos report provides an in-depth analysis of the overall market structure of Psoriatic Arthritis Treatment and assesses the possible changes in the current as well as future competitive scenarios of the Psoriatic Arthritis Treatment market. Reflecting the pandemic effects, the report also includes information regarding the changing market scenario, competition landscape of the companies, and the flow of the global supply and consumption.

Besides describing the market positions of various major key players for the Psoriatic Arthritis Treatment market, the report makes a concrete assessment on the key strategies and plans formulated by them over the recent years. In addition to this, the report provides information about recent developments such as product launch, entering merger and acquisition, partnership and collaboration, and expansion of the production plants by some key players.

This report includes the estimation of market size for value (USD) and volume (K MT), with applying top-down and bottom-up approaches to estimate and validate the overall scope of the Psoriatic Arthritis Treatment market. The report is prepared with a group of graphical representations, tables, and figures which displays a clear picture of the developments of the products and its market performance over the last few years. With this precise report, it can be easily understood the growth potential, revenue growth, product range, and pricing factors related to the Psoriatic Arthritis Treatment market.

Request a sample before buying this report @ https://dataintelo.com/request-sample/?reportId=118149

The published report consists of a robust research methodology by relying on primary source including interviews of the company executives & representatives and accessing official documents, websites, and press release of the companies related to the Psoriatic Arthritis Treatment market. It also includes comments and suggestions from the experts in the market especially the representatives from government and public organizations as well as international NGOs. The report prepared by DataIntelo is known for its data accuracy and precise style, which relies on genuine information and data source. Moreover, customized report can be available as per the clients wishes or specific needs.

Key companies that are covered in this report:

Eli LillyRocheMerckNovartisAbbvieAmgenBristol Myers SquibbCelgene CorporationJanssenValeant Pharmaceuticals

*Note: Additional companies can be included on request

The report covers a detailed performance of some of the key players and analysis of major players in the industry, segments, application, and regions. Moreover, the report also considers the governments policies in different regions which illustrates the key opportunities as well as challenges of the market in each region.

By Application:

HospitalsClinicsAmbulatory Surgery CentersDiagnostic Laboratories

By Type:

KitsReagentsInstruments

As per the report by DataIntelo, the Psoriatic Arthritis Treatment market is projected to reach a value of USDXX by the end of 2026 and grow at a CAGR of XX% through the forecast period (2020-2026). The report describes the current market trend of the Psoriatic Arthritis Treatment in regions, covering North America, Latin America, Europe, Asia Pacific, and Middle East & Africa by focusing the market performance by the key countries in the respective regions. According to the need of the clients, this report can be customized and available in a separate report for the specific region.

You can also go for a yearly subscription of all the updates on Psoriatic Arthritis Treatment market.

You can buy the complete report @ https://dataintelo.com/checkout/?reportId=118149

Why you should buy this report?

This report provides a complete guideline for the clients to arrive an informed business decisions since it entails a comprehensive information, which will help the clients to understand better of the current & future market situation.

Apart from that, the report also answers some of the key questions given below:

If you have any questions on this report, please reach out to us @ https://dataintelo.com/enquiry-before-buying/?reportId=118149

About DataIntelo

DataIntelo is a globally leading market research company that has an excellent group of long-year experienced team in the field of business research. We keep our priority to fulfil the needs of our customers by offering authentic and inclusive reports for the global market-related domains. With a genuine effort from a dedicated team of business experts, DataIntelo has been in the service for years by providing innovative business ideas and strategies for the current global market for various industries and set its benchmark in the market research industry.

We have a large support of database from various leading organizations and business executives across the globe. With this leverage, we excel at customized report as per the clients requirement and updating market research report on the daily basis with quality information.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Continue reading here:
Psoriatic Arthritis Treatment Market To 2026: Growth Analysis By Manufacturers, Regions, Types And Applications - The Market Feed

BOULDER, Colo. The CBDMEDIC brand, now part of the Charlottes Web, Inc. family of hemp CBD wellness products, and an official Impact Sponsor for the Arthritis Foundation, announces its matching funds campaign for Giving Tuesday. On Dec. 2nd CBDMEDIC will match individual donations made to the Arthritis Foundation up to a total sum of $50,000.

To those on Giving Tuesday who donate $50 or more to the Arthritis Foundation, CBDMEDIC will ship a free thank you gift of its Arthritis Aches and Pain Relief Cream, a retail value of $39.99 The Arthritis Foundation continues to pursue a cure for Americas number one cause of disability, and provides advocacy, community connections, and educational resources to those battling arthritis. The Giving Tuesday donations and CBDMEDIC matching funds donation will support scientific research, legislation and life-improvement programs led by the Arthritis Foundation. CBDMEDIC is the only hemp CBD brand to be approved and serve as an Arthritis Foundation Impact Sponsor.

According to GivingTuesday.org, last year more than 13% of the U.S. population participated in Giving Tuesday raising $511M online to support thousands of nonprofits. To participate in the CBDMEDICs Giving Tuesday Matching Funds Campaign donors may link here beginning at midnight Dec. 1 through midnight Dec. 2, 2020.

The Arthritis Foundation is leading the charge to find solutions that make a life-changing impact for people with arthritis. Partnering with CBDMEDIC helps bring greater awareness around the challenges of living with arthritis, which includes managing chronic pain, said Rick Willis, Senior Vice President, Community Engagement. We appreciate their commitment to providing the arthritis community with topical alternatives for temporary pain relief.

Especially in these uncertain times, due to the pandemic, it is vitally important that businesses and their brands step up and support nonprofits like the Arthritis Foundation this Giving Tuesday, said Deanie Elsner, CEO of Charlottes Web, Inc. Our CBDMEDIC brand is offering $50,000 in matching funds so that the Arthritis Foundations work in scientific research and advocacy can continue to benefit the millions of Americans suffering from arthritis. This is also a part of our Charlottes Web mission to help people heal through compassion and science. We encourage everyone who is able to do so to give this Giving Tuesday to the Arthritis Foundation.

According to the Center for Disease Control, 22.7% of adults in US have doctor-diagnosed arthritis (or one in four adults). And, About 43.5% (or 23.7 million) of people with arthritis (54.4 million) have limitations in their daily activities due to their arthritis.

CBDMEDIC is now part of the Charlottes Web family of hemp-derived CBD brands sold online <https://www.charlottesweb.com/cbd-medic>, as well as in more than 4,500 retail stores, according to Nielsen data (9/5/2020). CBDMEDIC top-selling products for those suffering from the symptoms of arthritis, as well as pain and inflammation, include its Back & Neck Pain Relief Ointment, Arthritis Aches & Pain Relief Ointment, Arthritis Aches & Pains Hand Cream, Active Sport Pain Relief Stick, Muscle & Joint Pain Relief Spray and Muscle & Joint Pain Relief Ointment.

Find out more about CBDMEDIC topical pain relief products.

About the Arthritis Foundation:The Arthritis Foundation is the Champion of Yes. Leading the fight for the arthritis community, the Foundation helps conquer everyday battles through life-changing information and resources, access to optimal care, advancements in science and community connections. The Arthritis Foundations goal is to chart a winning course, guiding families in developing personalized plans for living a full life and making each day another stride toward a cure. Visit arthritis.org to learn more.

About CBDMEDICLaunched in 2019 and now sold in more than 4,500 retail stores, the CBDMEDIC brand offers a line of 15 THC-free and hemp-derived CBD topical pain relief products that provide revolutionary pain relief. CBDMEDIC products combine naturally derived pain-relieving pharmaceutical ingredients along with natural emollients (skin softening ingredients) and essential oils, and THC-free hemp extract to create unique formulations for fast and effective relief. CBDMEDIC formulations combine advanced science with organic and natural ingredients to provide safe relief. CBDMEDIC products are offered across the United States and are produced by a contract manufacturer in a cGMP compliant and audited manufacturing facility.

About Charlottes Web Holdings, Inc.Charlottes Web Holdings, Inc., a Certified B Corporation headquartered in Boulder, Colo., is the market leader in the production and distribution of innovative hemp-derived cannabidiol (CBD) wellness products under a family of brands which includes Charlottes Web, CBD Medic, CBD Clinic, and Harmony Hemp. The Companys premium quality products start with proprietary hemp genetics that are 100-percent American farm grown and manufactured into whole-plant hemp extracts containing a full spectrum of naturally occurring phytocannabinoids including CBD, CBC, CBG, terpenes, flavonoids and other beneficial hemp compounds. Charlottes Web product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, stress, inflammation recovery), CBD capsules, CBD topical creams and lotions, as well as CBD pet products for dogs. Charlottes Web is the number one CBD brand in the USA and distributed through more than 22,000 retail locations, select distributors and online through the Companys website at http://www.CharlottesWeb.com.

Charlottes Web was founded by the Stanley Brothers with a mission to unleash the healing powers of botanicals through compassion and science, benefiting the planet and all who live upon it. Charlottes Web is a socially and environmentally conscious company and is committed to using business as a force for good and a catalyst for innovation. The Company weighs sound business decisions with consideration for how its efforts affect employees, customers, the environment, and diverse communities. The rate the Company pays for agricultural products reflects a fair and sustainable rate driving higher quality yield, encouraging regenerative farming practices, and supporting U.S. farming communities. Management believes that its socially oriented and environmentally responsible actions have a positive impact on its customers, suppliers, employees and stakeholders. Charlottes Web donates a portion of its pre-tax earnings to charitable organizations.

Read the original here:
CBDMEDIC to Match $50000 in Funds for Arthritis Foundation on Giving - CBD Today

You have one sacroiliac (SI) joint on either side of your body where your ilium and sacrum bones join together. Your sacrum is the wide, flat bone between your tailbone and lumbar spine. Your ilium is often referred to as your hip bone.

Unlike many other joints like your knee or elbow, your SI joint moves very little and is held together with thick ligaments. Sudden injuries or repetitive stress can cause the SI joint to become inflamed and painful. You may feel this pain in your buttocks or lower back.

Sitting for extended periods of time can lead to pain in your SI joint or aggravate existing pain. However, certain positions are less likely to cause pain than others.

Keep reading to learn the best sitting, standing, and lying positions if youre dealing with SI joint pain.

The ligaments in your SI joint help transfer force between your trunk and your leg when performing activities like walking or running. If youre dealing with SI joint pain, sitting in positions that put these ligaments under tension may lead to further pain and irritation.

When sitting in a chair, you should aim to keep your hips neutral to avoid excess stress on the ligaments in your SI joint. Think about keeping your hips level with each other and avoid rotating more to one side.

Avoid positions that hike one hip higher or put create an asymmetry in your hips, such as when you cross your legs.

Heres how you can sit with good posture to help manage SI joint pain:

The tailors position is another option for keeping your pelvis neutral and reducing stress on the ligaments on your SI joint. You should focus on keeping your hips symmetrical.

If sitting is giving you pain, you may want to alternate between sitting and standing. If youre using a standing desk, heres how you can set it up:

Chair exercises and stretches may help you reduce pain and stiffness around your SI joint and help strengthen muscles around the joint.

This simple seated backbend stretch may help you reduce lower back stiffness.

The seated cat-cow stretches and strengthens the muscles in your back and core.

A seated torso stretch is an easy way to mobilize your spine.

The seated hamstring stretch helps you loosen your hamstrings and may help alleviate pain from muscle imbalances.

If you spend a lot of time sitting at a desk, finding a comfortable office chair may help you reduce SI joint pain. You should look for:

No matter what chair youre sitting in, its a good idea to take frequent breaks from sitting about every 30 minutes.

Many people with SI joint pain find that it gets worse when they stand for extended periods of time.

Standing with good posture can help keep your spine in alignment and may help you manage your SI joint pain. When standing:

Its generally best to avoid sleeping on your stomach if youre dealing with neck or back pain. Sleeping on your stomach puts more stress on your spine. If you do sleep on your stomach, try putting a pillow beneath your abdomen.

If youre having SI joint pain on one side, you may want to sleep on your opposite side to take your weight off the joint. Putting a pillow between your knees and ankles can help put your hips in alignment.

Another sleeping posture to take the stress off your SI joint is to sleep on your back with one or two pillows under your knees to put your hips in a neutral posture.

If youre dealing with SI joint pain, you should aim to sit with your hips neutral and with your lower back relaxed and supported. If your chair doesnt provide support, you can put a pillow or cushion behind your lower back.

Even if you sit with perfect posture, taking frequent breaks about every 30 minutes is important.

Go here to see the original:
How to Sit with SI Joint Pain: Posture and Seated Exercises - Healthline

High disease activity in early rheumatoid arthritis (RA) is correlated with depression and anxiety, according to study results published in RMD Open. Depression and anxiety were also found to be more prevalent among patients with poor self-reported functional status.

The Scottish Early Rheumatoid Arthritis (SERA) inception cohort included patients with new-onset RA who received care at rheumatology centers in Scotland between 2011 and 2015. Baseline demographic and clinical data of patients were collected within 6 months of RA diagnosis, with follow-up visits conducted after 6 and 12 months.

The primary study outcome was depression and anxiety symptoms, measured using the Hospital Anxiety and Depression Scale. Exposures of interest included disease activity, functional status, and laboratory parameters. Disease activity was measured using the Disease Activity Score-28 (DAS28) and the patient global assessment visual analog scale (PGA-VAS); functional status was measured using the Health Assessment Questionnaire (HAQ). Erythrocyte sedimentation rate, C-reactive protein (CRP) levels, rheumatoid factor positivity, and anticyclic citrullinated peptides status were also recorded. Multivariable linear regression was performed to assess the relationship between anxiety and depression scores and various demographic and clinical variables.

The study cohort included 848 patients with RA (mean age, 58.2713.71 years; mean DAS28 score, 4.951.41), among whom 70.0% were women. At 6 and 12 months, follow-up data of 691 and 618 participants with RA, respectively, were available for evaluation.

No significant differences in depression or anxiety symptoms were observed between patients who continued follow-up and those who dropped out of the study. The baseline prevalence of anxiety and depression was higher among patients with early RA vs healthy individuals (19.0% vs 1.7% and 12.2% vs 1.75; P =.0002 and P =.009, respectively). However, prevalence of anxiety and depression in early RA decreased to 13.4% and 8.1%, respectively, at 12 months. Depression and anxiety scores were significantly positively associated with DAS28 at baseline, 6 months, and 12 months (all P <.001).

Multivariable linear regression models showed that baseline anxiety was associated with younger age (P =.001) and higher HAQ score (P <.0001). Anxiety at the 6-month follow-up was negatively correlated with body mass index (P =.015) and positively associated with baseline anxiety (P <.0001), current HAQ score (P =.006), and higher current PGA-VAS score (P =.008). Similar associations were observed at 12 months.

Baseline depression was associated with younger age (P =.029), being single at the time of measurement (P =.022), and a higher current HAQ score (P <.001). Depression at 6 months was associated with higher baseline depression (P <.0001) and anxiety (P =.002) scores, higher current HAQ score (P <.0001), and greater current CRP levels (P =.009). The same associations persisted at 12 months. At 6 months only, men were more likely than women to have depression.

These results suggested that anxiety and depression were prevalent in early RA, particularly among those with greater disease activity and poorer self-reported functioning. Although anxiety and depression rates appeared to decrease during follow-up, they were still reported at rates higher than those observed in the general population.

The primary study limitation included the fact that more than 200 participants had been lost to follow-up by 12 months. In addition, data were only available at 6-month intervals, which prevented a more precise assessment of mood during all timepoints.

Our study indicates that clinicians should be alert to neuro-psychiatric comorbidity in RA from the earliest stages of the disease, the researchers wrote. [I]t remains to be determined whether more intense screening and treatment for psychiatric comorbiditiescan improve outcomes.

Disclosure: The SERA cohort was supported by Pfizer Inc. Please see the original reference for a full list of authors disclosures.

Reference

Fragoulis GE, Cavanagh J, Tindell A, et al. Depression and anxiety in an early rheumatoid arthritis inception cohort. associations with demographic, socioeconomic and disease features. RMD Open. 2020 Oct;6(3):e001376.

Read this article:
Depression and Anxiety Associated With Disease Activity, Functional Status in Early RA - Rheumatology Advisor

Objective:To estimate the annual cost associated with obstetric events in women of reproductive age with immune-mediated inflammatory diseases, from the perspective of the National Healthcare System.

Methods:A cost-analysis was developed to estimate the impact associated with obstetric events in women of reproductive age with psoriasis (PSO), psoriatic arthritis (PsA), rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA). The analysis considered complications during fertility and conception, in pregnancy and in the postpartum. All parameters were validated and agreed by a multidisciplinary expert panel. Unitary costs (, 2019) were obtained from national, local databases.

Results:During fertility and conception, an annual cost per patient of 229 was estimated for a preconception consultation in a patient with PSO, of 3,642 for a preconception consultation in patients with PsA, RA and axSpA and 4,339 for assisted reproduction. Women with complications in pregnancy had an annual cost per patient of 1,214 for a miscarriage in the first trimester, 4,419 for a late miscarriage in the second trimester, 11,260 for preeclampsia 3,188 for restricted intrauterine growth and 12,131 for threat of premature delivery. In the postpartum, an annual cost per patient of 120,364, 44,709, and 5,507 were estimated associated with admissions to neonatology of premature infants of <28, 28-32 and 33-37 weeks, respectively.

Conclusions:This analysis provides insight on the economic burden of complications associated with women of reproductive age for immune-mediated diseases (PSO, PsA, RA, axSpA). Individualization of treatment, additional and close monitoring may reduce the risk and burden of these complications.

Keywords:Anlisis de costes; Complicaciones materno-fetales; Cost-analysis; Enfermedades reumticas; Espaa; Eventos obsttricos; Maternal-foetal complications; Obstetric events; Rheumatic diseases; Spain.

See the original post here:
Economic Impact of Obstetric Events on Women of Reproductive Age Living With Psoriatic Arthritis, Rheumatoid Arthritis, Axial Spondyloarthritis and...

This article was originally published here

Rheumatol Int. 2020 Nov 30:1-10. doi: 10.1007/s00296-020-04751-w. Online ahead of print.

ABSTRACT

Nationwide lockdowns during SARS-CoV-2 (COVID-19) can compromise mental health and psychological wellbeing and limit opportunities for physical activity (PA), particularly in clinical populations, such as people with rheumatoid arthritis (RA), who are considered at risk for COVID-19 complications. This study aimed to investigate associations between PA and sedentary time (ST) with indicators of mental health and wellbeing in RA during COVID-19 lockdown, and examine the moderation effects of self-isolating. 345 RA patients completed an online questionnaire measuring PA (NIH-AARP Diet and Health Study Questionnaire), ST (International Physical Activity Questionnaire-Short Form), pain (McGill Pain Questionnaire and Visual Analogue Scale), fatigue (Multidimensional Fatigue Inventory), depressive and anxious symptoms (Hospital Anxiety and Depression Scale), and vitality (Subjective Vitality Scale) during the United Kingdom COVID-19 lockdown. Associations between PA and ST with mental health and wellbeing were examined using hierarchical multiple linear regressions. Light PA (LPA) was significantly negatively associated with mental fatigue ( = .11), depressive symptoms ( = .14), and positively with vitality ( = .13). Walking was negatively related to physical fatigue ( = .11) and depressive symptoms ( = .12) and positively with vitality ( = .15). Exercise was negatively associated with physical ( = .19) and general ( = .12) fatigue and depressive symptoms ( = .09). ST was positively associated with physical fatigue ( = .19). Moderation analyses showed that LPA was related to lower mental fatigue and better vitality in people not self-isolating, and walking with lower physical fatigue in people self-isolating. These findings show the importance of encouraging PA for people with RA during a lockdown period for mental health and wellbeing.

PMID:33258004 | PMC:PMC7703721 | DOI:10.1007/s00296-020-04751-w

Here is the original post:
Different types of physical activity are positively associated with indicators of mental health and psychological wellbeing in rheumatoid arthritis...

There are very few things that bring more joy in our lives than having a pet dog. If youre a pet parent, you must be already familiar with the fantastic health benefits of having a dog at home. Also, house pets have a positive impact on your mental well-being and can even help you cope with grief and loneliness. Once they become a part of your family, its your responsibility to care for them.

If we could have our way, wed want our canine companions to be a part of our lives forever. But, unfortunately, theyre going to grow old and become fragile and weak. Activities that once happened naturally, such as jumping down the stair and running around in the park, are going to need more effort. On top of that, your dog might become susceptible to various chronic diseases.

Canine osteoarthritis, a chronic condition, can cause extreme pain and discomfort to your dog. It affects at least 20% of dogs whore over one-year-old. While theres no way to completely cure canine arthritis, theres a lot you can do to help your dog when theyre in pain.

In this blog, well dive deeper into the topic of canine arthritis and understand what causes it. Well also outline the signs and symptoms you should watch out for, as well as recommend a few pain management techniques. Lets get started.

Canine arthritis is a chronic ailment that causes stiffness and joint pain in dogs. It happens when the cartilage tissue protecting the bones in a joint starts degenerating. In a healthy joint, the cartilage between the bones is lubricated with a fluid. This prevents the bones from coming in direct contact and rubbing together.

If the cartilage tissue starts decaying as a result of an injury or old age, the bones come in direct contact with each other. As the bones rub together, it causes extreme pain and inflammation in the joints. It can also result in the growth of new bones (called osteophytes) that further intensify the pain.

Moreover, when the cartilage cells degenerate, they release certain enzymes that cause inflammation of the joints. It also leads to excessive fluid buildup in the joints. All these factors amplify the pain and can even result in mobility issues as well as muscular atrophy.

While canine osteoarthritis can affect dogs of any age and breed, there are a few potential risk factors such as:

There isnt much you can do to prevent your dog from developing a chronic ailment like arthritis. However, the earlier you notice their symptoms and consult a veterinarian, the better their quality of life will be.

As a dog parent, here are a few signs and symptoms you should watch out for:

Its worth mentioning here that dogs are often very adept at hiding their pain. Thats why you need to be extra cautious and start paying attention to their gait and posture the moment you notice any signs of pain in your dog.

Unfortunately, canine arthritis is an irreversible degenerative disease. Once the cartilage cells start dying, theres no way to regenerate them and make the joints healthy again. Having said that, you can use a wide array of pain-relieving techniques to help dogs with osteoarthritis.

Here are a few things you can do to help your dog if they develop osteoarthritis:

The key to managing canine arthritis is to minimize pain and inflammation in the joints. A non-steroidal inflammatory drug (NSAID) such as Previcox, treats arthritic pain in dogs by reducing inflammation. However, the symptoms of canine arthritis overlap with those of several other ailments.

Your dog might just be in pain because of a bone injury. Or the symptoms could be an indication of a more serious disease such as cancer. Thats why it is important to first consult your vet and ask for a suitable treatment plan.

Typically, the doctor will conduct a physical exam of your dogs body. Theyll also likely recommend an X-ray of the limbs. Depending on whether they detect signs of arthritis, theyll recommend the course of treatment.

Consult your vet to create a balanced and nourishing diet plan thats rich in anti-inflammatory and whole foods such as turmeric, ginger, fatty fishes, and leafy vegetables. You could also consider including Omega-3 supplements in their diet. Make sure you avoid inflammatory and unhealthy foods that could trigger more pain.

If your dog is in pain, theyll become unwilling to go on walks or engage in regular physical activities. However, they dont get adequate exercise; theyll likely put on more weight, potentially becoming obese, and developing more pain. Make sure you talk to your vet and work out a less taxing exercise routine for your dog.

Depending on your dogs age and physical health, the vet might suggest pain-relieving therapies such as acupuncture, hydrotherapy, physiotherapy, etc. These techniques can go a long to alleviate the pain and improve your four-legged friends overall quality of life.

Recent studies have also shown that CBD oil can help relieve arthritic pain in dogs. However, it could also have potential side effects such as gastrointestinal disorders. Make sure you consult your vet and ask them to prescribe the suitable dosage for your dog.

Have you used any other pain management techniques to help an arthritic dog? Share your suggestions in the comments section below.

Visit link:
Canine arthritis Its a real thing that pet parents need to be prepared for - TechEngage

Visit the News Hub

In mouse study, loss of molecule contributes to disease while surplus reduces symptoms

Researchers at Washington University School of Medicine in St. Louis have found, working in mice, that when the FoxO1 gene is knocked out, the animals develop osteoarthritis. But when levels of the FoxO1 molecule are increased, the animals exhibit less cartilage damage.

Osteoarthritis is one of the most common problems associated with aging, and although there are therapies to treat the pain that results from the breakdown of the cartilage that cushions joints, there are no available therapies to modify the course of the disease.

However, working in a mouse model of the disorder, researchers at Washington University School of Medicine in St. Louis have found that a molecule previously linked to diabetes, cancer and muscle atrophy also seems to be involved in the development of osteoarthritis and may be a useful treatment target.

When the gene involved, FoxO1, is knocked out in mice, the animals develop osteoarthritis. But when the researchers increase the levels of the FoxO1 molecule in mice that are developing osteoarthritis, the animals exhibit less cartilage damage.

The study is available online in Proceedings of the National Academy of Sciences.

Osteoarthritis, or joint degeneration, is a disease that affects more than 32 million people in the U.S. alone but that does not have a medical therapy to alter its progression, said senior investigator Regis J. OKeefe, MD, PhD, the Fred C. Reynolds Professor of Orthopaedic Surgery and head of the Department of Orthopaedic Surgery. A better understanding of the fundamental processes involved in osteoarthritis and the degeneration of cartilage is required if were going to be more successful in treating this very common and very expensive disorder.

OKeefe said that commonly, people with osteoarthritis have suffered knee injuries that damaged the knees meniscus. Over time, arthritis then can develop in the joint.

Unlike skin or bone or other organs that can regenerate in response to injury, cartilage has very little regenerative potential, he said.

However, when the mice in these experiments had elevated levels of the FoxO1 molecule, osteoarthritiss progress was slowed or even reversed. The researchers believe the molecule interferes with cartilage damage and the development of arthritis by enhancing a process called autophagy in the arthritic joint. Autophagy is the bodys way of clearing out damaged tissue. In these experiments, the researchers found that autophagy was disrupted in the mice with reduced levels of FoxO1 and that the process was enhanced in animals with higher levels of the molecule.

In other words, maintaining a higher level of autophagy seemed to be beneficial to maintaining these cartilage cells and, thus, maintaining a healthy knee joint, said co-corresponding author Jie Shen, PhD, an assistant professor of orthopedic surgery.

OKeefe said that raises the possibility of delivering FoxO1 to arthritic joints through nanotechnology as a way to regulate autophagy and keep joints healthier.

In mice with injuries that typically progress to become osteoarthritis, the knee joints still appear normal about a week after injury, OKeefe explained. But when we measure autophagy in the cartilage after injury to those same knee joints, although the joints themselves look fine, the autophagy process already is shut off. The injury completely turns it off, and once autophagy is off, the cartilage begins to degenerate.

He said if FoxO1 can alter that process in people, protecting cartilage from damage as it does in mice, it eventually may be possible to prevent or delay millions of future knee and hip replacement surgeries.

Wang C, Shen J, Ying J, Xiao D, OKeefe RJ. FoxO1 is a crucial mediator of TGFB/TAK1 signaling and protects against osteoarthritis by maintaining articular cartilage homeostasis. Proceedings of the National Academy of Sciences, Nov. 16, 2020.

This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH). Grant numbers R01 AR069605, T32 AR060719 and P30 AR057235.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

The rest is here:
Gene that protects against osteoarthritis identified Washington University School of Medicine in St. Louis - Washington University School of Medicine...

Jennifer May, M.D., Prairie Doc Published 9:33 p.m. CT Dec. 3, 2020

Jennifer May, M.D.(Photo: Submitted)

As a rheumatologist, I often get the question, What do you do? According to my kids, their mom does something with joints. At the conclusion of patient visits, when I propose a diagnosis such as polymyalgia rheumatica or PMR, I often hear, What is that? The fact is most people do not think about rheumatology until they need a rheumatologist. And then, learning the lingo about disease, medications, and lab monitoring can be a challenge.

Rheumatology is a relatively new specialty in the world of medicine. Focus on the disease in America began in the early 1920s with initial definition and discovery, followed by the famous breakthrough of cortisone at Mayo Clinic in 1950, and grew to a deeper scientific understanding of arthritis diseases today. Treatments have progressed from cortisone and aspirin to immune system modification with biologic medications. Future therapies will involve genetics, engineering new cartilage, and creating cells that rheumatologists will command to do our bidding upon the immune system.

Today we work to manage autoimmune diseases such as rheumatoid arthritis or lupus with medications that adjust the immune system response. Symptoms that can occur in association with some of these diseases are rashes, joint swelling, fevers, lung problems, and kidney issues. By adjusting the immune system, we can change the symptoms, hopefully lessening their impact on the patient.

In our fast-paced world, we often want answers and quick solutions to our problems. However, rheumatology cases require persistence. There are no blood tests that specifically diagnose the problem. Rheumatologists must take time to talk with and examine the patient. We gather additional information from labs tests, studies, and x-rays. Once all the data is available, sometimes the condition is clear. But other times, the case is more challenging and requires several visits before making a firm diagnosis.

Like most health providers, I enjoy solving patient problems and making a diagnosis. We get satisfaction from figuring things out and our reward comes when a treatment improves a patients function or quality of life. Our goal in rheumatology is to help patients achieve remission, or better yet, to predict who is likely to get rheumatoid arthritis in hopes of preventing it from starting in the first place.

So, when patients look at me with that expression that asks rheuma-what?, they dont necessarily want to hear about the science of what I do. Instead, I assure them that we will keep working together with the same goal: To get the immune system to quiet down, and help the patient feel better so they can get back to life.

Jennifer May, M.D. is a contributing Prairie Doc columnist. She practices rheumatology in Rapid City. Prairie Doc can be seenon SDPB most Thursdays at 7 p.m.

Read or Share this story: https://www.argusleader.com/story/news/brandon/2020/12/03/learning-what-rheumatologist/3820369001/

See the rest here:
Learning what it is to be a rheumatologist - Argus Leader

December 1 is Giving Tuesday, a holiday created to highlight nonprofits and other organizations that work locally and globally to spread generosity and giving. The movement began in New York City in 2012 and has since flourished into an international event. The movement continues to grow in year-over-year donation volume, reach, and impactdriving increased donations and behavior change, said GivingTuesday.org.

In 2019, at least $1.97 billion were donated in 24 hours [during Giving Tuesday] in the U.S. alone, with 13 percent of the adult population participating in some waya record-setting day. Around the world, the majority of people aware of Giving Tuesday say that it has inspired them to be more generous, the nonprofit added.

Its hard to quantify or overestimate the power of goodwill, particularly this year when the holidays will be so different, for so many. A gesture of kindness, big or small, can make a lot of difference to a friend or co-worker, neighbors or children, or those less fortunateits the joy of giving that warms the heart and makes memories for years to come.

This year, which is like no other in our lifetime, is a real game-changer for charities and the people they benefit, though. Its a diverse cross-section of Americansincluding cannabis industry memberswho keep giving. And thank goodness for that, because this year every dollar counts. The help you give will be warmly appreciated and rememberedso, give until it feels good.

Vape manufacturer PAX Labs partnered with nonprofit Last Prisoner Project to host a fundraiser benefiting more than 40,000-plus people in prison for cannabis offenses. Today and tomorrow, December 12, 2020, every donation of $25 or more will be entered to win one of twenty free PAX 3 Complete Kit cannabis vaporizers.

The PAX fundraiser directly benefits LPP, which recently helped win clemency for Americas longest serving, non-violent cannabis offender, Richard DeLisi. Anyone who would like to donate for a chance to win one of the free PAX vape kits (or any amount) should visit PAX Giving Tuesday.

Edibles manufacturer MONDO Meds is offering a free jar of its CBD-infused powder supplement to firefighters, healthcare, and government workers. Each 4-ounce jar contains 150mg CBD in a rich, powdered formula that can be added to beverages or food. Front line workers may contact [emailprotected] to request a free jar ($40.00 MSRP), when they email a picture of their government ID and best delivery address.

With many essential workers serving on the front lines of multiple natural disasters and experiencing so much anxiety and stress, CBD brands are also making contributions aimed at showing appreciation to these heroes.

As an official Impact Sponsor for the Arthritis Foundation, Charlottes Webs CBDMEDIC brand will match individual donations made to the Arthritis Foundation on Giving Tuesday up to a total sum of $50,000. Those who donate $50 or more will receive a gift of CBDMEDICs Arthritis Aches and Pain Relief Cream.

Especially in these uncertain times, due to the pandemic, it is vitally important that businesses and their brands step up and support nonprofits like the Arthritis Foundation this Giving Tuesday, said Charlottes Web Chief Executive Officer Deanie Elsner, We encourage everyone who is able to do so to give this Giving Tuesday to the Arthritis Foundation.

If you would like to donate to the Arthritis Foundation as part of the CBDMEDIC fundraiser click here for more information.

Etain Health, New Yorks only family-run, women-owned and operated, medical marijuana company and lifestyle brand Buy Weed From Women (BWFW) have teamed up for a fundraiser to benefit the Food Bank for New York, a nonprofit that has been working to end food poverty in New Yorks five boroughs for over 36 years.

The collaboration between Etain and BWFW has resulted in the Goods Box, a limited edition collection featuring BWFW merchandise including a long-sleeve tee and face covering and more good surprises. The box goes on sale December 3, at EtainHealth.com and proceeds will benefit the food bank.

See the original post:
December 1 is Giving Tuesday, a holiday created to highlight nonprofits and other organizations that work - mg Magazine

The Global Rheumatoid Arthritis (RA) Drugs Market analysis report published on dataintelo is a detailed study of market size, share and dynamics covered in XX pages and is an illustrative sample demonstrating market trends. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth and profitability. The report also delivers on key players along with strategic standpoint pertaining to price and promotion.

Get FREE Exclusive PDF Sample Copy of This Report: https://dataintelo.com/request-sample/?reportId=94401

The Global Rheumatoid Arthritis (RA) Drugs Market report entails a comprehensive database on future market estimation based on historical data analysis. It enables the clients with quantified data for current market perusal. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and regional analysis. Listed out are key players, major collaborations, merger & acquisitions along with upcoming and trending innovation. Business policies are reviewed from the techno-commercial perspective demonstrating better results. The report contains granular information & analysis pertaining to the Global Rheumatoid Arthritis (RA) Drugs Market size, share, growth, trends, segment and forecasts from 2020-2026.

With an all-round approach for data accumulation, the market scenarios comprise major players, cost and pricing operating in the specific geography/ies. Statistical surveying used are SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics. Graphs are clearly used to support the data format for clear understanding of facts and figures.

Customize Report and Inquiry for The Rheumatoid Arthritis (RA) Drugs Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=94401

Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Primary research, interviews, news sources and information booths have made the report precise having valuable data. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

The report segments the Global Rheumatoid Arthritis (RA) Drugs Market as:Global Rheumatoid Arthritis (RA) Drugs Market Size & Share, by Regions

Global Rheumatoid Arthritis (RA) Drugs Market Size & Share, by ProductsOralInjectionExternal

Global Rheumatoid Arthritis (RA) Drugs Market Size & Share, ApplicationsMedical CarePersonal Care

Key PlayersAbbVieRocheJohnson & JohnsonAmgen, Inc.PfizerMerckBristol-Myers SquibbUCBGlaxoSmithKlineSanofiAbbott LaboratoriesTeva Pharmaceutical

Avail the Discount on this Report @ https://dataintelo.com/ask-for-discount/?reportId=94401

Dataintelo offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

View post:
Rheumatoid Arthritis (RA) Drugs Market 2020 Industry Size, Trends, Global Growth, Insights And Forecast Research Report 2025 - Murphy's Hockey Law

The Rheumatoid Arthritis Diagnosis Tests Market grew in 2019, as compared to 2018, according to our report, Rheumatoid Arthritis Diagnosis Tests Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Rheumatoid Arthritis Diagnosis Tests Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025

Deep analysis about market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Rheumatoid Arthritis Diagnosis Tests Market

Get a Sample Copy of the Report at: https://i2iresearch.com/report/global-rheumatoid-arthritis-diagnosis-tests-market-2020-market-size-share-growth-trends-forecast-2025/#download-sample

The Rheumatoid Arthritis Diagnosis Tests Market is analysed based on product types, major applications and key players

Key product type:Serology TestsMonitoring RA Treatment Efficiency Tests

Key applications:Diagnostic LaboratoriesAmbulatory Surgical CentersHospitals

Key players or companies covered are:AbbottBeckman CoulterEuro DiagnosticaRocheQiagenSiemens HealthcareThermo Fisher ScientificBio Rad LaboratoriesAviva Systems Biology

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/report/global-rheumatoid-arthritis-diagnosis-tests-market-2020-market-size-share-growth-trends-forecast-2025/

Key questions answered in the report:1. What is the current size of the Rheumatoid Arthritis Diagnosis Tests Market, at a global, regional & country level?2. How is the market segmented, who are the key end user segments?3. What are the key drivers, challenges & trends that is likely to impact businesses in the Rheumatoid Arthritis Diagnosis Tests Market?4. What is the likely market forecast & how will be Rheumatoid Arthritis Diagnosis Tests Market impacted?5. What is the competitive landscape, who are the key players?6. What are some of the recent M&A, PE / VC deals that have happened in the Rheumatoid Arthritis Diagnosis Tests Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us:i2iResearch info to intelligenceLocational Office: *India, *United States, *GermanyEmail: [emailprotected]Toll-free: +1-800-419-8865 | Phone: +91 98801 53667

View post:
Rheumatoid Arthritis Diagnosis Tests Market by Analysis, Market Dynamics, Regions, Consumption, Production, Suppliers and Forecast 2026 - Cheshire...

In the first wave of the coronavirus disease 2019 pandemic, patients with axial spondyloarthritis, rheumatoid arthritis, and psoriatic arthritis didnt have an increase in disease activity despite an interruption in in-person interactions.

During the first wave of the coronavirus disease 2019 (COVID-19) pandemic, patients with axial spondyloarthritis (axSpA), rheumatoid arthritis (RA), and psoriatic arthritis (PsA) didnt see any increase in disease activity despite an interruption in in-person interactions, according to research published in Annals of Rheumatic Diseases.

The researchers analyzed patients in the Swiss Clinical Quality Management cohort to understand how partial or complete closure of rheumatology services impacted disease activity as remote consultations were used to partly compensate for the reduced in-person interaction.

Additional factors may also potentially contribute to disease worsening during the pandemic, the authors explained. Some patients may choose to preventively stop immunosuppression out of fear of complications. Moreover, the psychological stress (anxiety about a new disease, economic pressure, less recreational opportunities and so on) encountered during the pandemic should not be underestimated.

The researchers defined 3 study periods: a preCOVID-19 phase from January 1 to February 29, 2020; a COVID-19 phase from March 1 to April 30, 2020; and a postCOVID-19 phase from May 1 to June 30, 2020. Patients who had at least 1 patient-reported disease activity measure in each of the study periods were included.

A few disease activity assessments were used: the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for axSpA; the Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5) in RA; and the Patient Global Assessment (PGA) visual analogue scale for disease activity in PsA. The researchers used the following to define a clinically important worsening:

The study looked at 287 patients with axSpA, 248 with RA, and 131 with PsA. The number of visits dropped 52% from 543 in February to 262 in April; however, there was a 129% increase in web-based application entries (521 to 1195) during this time.

In the preCOVID-19 phase, 15% of patients were nonadherent to their medication. While there was a slight increase in nonadherence during the COVID-19 phase, the researchers noted the increase only reached statistical significance among patients with axSpA.

Adherence returned to prepandemic levels in the postCOVID-19 phase, they wrote.

Over the first half of 2020, patient-reported disease activity outcomes were stable. There was a slight decrease during the COVID-19 phase; the decrease was only statistically significant for patients with axSpA (mean BASDAI 3.40 before the pandemic and 3.23 during the pandemic; P = .02). There was disease flare in less than 15% of patients for all 3 diseases, which was not statistically different from the preCOVID-19 phase.

The authors noted that the fact they could only evaluate patients with regular disease activity assessments was a limitation.

This subset using the smartphone app is probably more invested in disease management and the non-compliance figures might be under-represented, they wrote.

Reference

Ciurea A, Papagiannoulis E, Brki K, et al. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. Published online September 22, 2020. doi:10.1136/annrheumdis-2020-218705

Read more from the original source:
Interruptions to In-Person Visits During Pandemic Did Not Negatively Impact Patients With Inflammatory Arthritis - AJMC.com Managed Markets Network

I harassed my GP enough to get it caught early

Meet Georgie.

At age 26, Georgie was diagnosed with rheumatoid arthritis, an autoimmune inflammatory condition that affects up to1% of the population worldwide.

Suffering from such incredible pain every morning that stopped her from doing simple things like getting dressed or brushing her teeth, Georgie sought help. And refused to stop until she got answers.

What we can learn from Georgies story

Georgies story is a positive one, one where the short time to diagnosis (23 months) meant that the disease was caught and treated early, causing minimal damage to her joints. So what contributed to this?

On the one hand, time-lags between initial symptoms and diagnosis for rheumatoid arthritis have universally decreased in recent years (egfrom 24 months in 20002002 to 6 months in 20092011). Key to this has probably been a shift in clinicians knowledge of the disease and the motivation to treat likely tied to their beliefs about the consequences of the disease and the impact of early diagnosis.

At the same time, patient empowerment remains an integral driver to accelerating diagnosis and treatment.

And Georgie is a great example of a patient who empowered herself by asserting her interests.

She had an awareness of her own body and what is normal. So when her doctors initially sent her home, she didnt give up within 2 weeks, she was back, asking for answers. When the blood tests came back normal, she wasnt demoralised. Her awareness, together with the desire to live pain-free, gave her the motivation and confidence to assert her interests in her interactions with healthcare professionals and persist until a referral and diagnosis were reached.

But she shouldnt have to empower herself

Georgies success comes from being assertive and not all patients will be. So what about them? Will they end up with a delayed diagnosis and the consequent joint damage that goes with it?

Communication is key here; and both parties need to be involved. The environment has to engage patients and give them the knowledge, confidence and skills they need to be active players in their care. Which will be necessary to bridgethe gap between patients and doctors and enable them to share the knowledge they each have and help them make informed mutual decisions.

Clearly great strides have been made in rheumatoid arthritis. But we cant pause now; by looking at stories like Georgies, we have to keep assessing the gaps and continuously evolve the environment.

See more here:
The other side of rheumatoid arthritis - PMLiVE

DelveInsight's Rheumatoid Arthritis report states that the therapeutic market is expected to grow because of the launch of emerging drugs in the pipeline however the growth during the forecast period will be dampened because of the entry of biosimilars of blockbuster drugs

LAS VEGAS, Oct. 29, 2020 /PRNewswire/ -- The Rheumatoid Arthritis market report delivers an in-depth understanding of the Rheumatoid Arthritis, historical and forecasted epidemiology as well as the Rheumatoid Arthritis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan for the study period of 2017-2030.

Few of the key highlights from the report:

The Biologics segment holds the highest share in the market in terms of revenue; its approximately 90% of the market share. Among the biologics, its anti-TNFs (~68%) have captured the major portion of the market owing to well-established efficacy, safety profile, physicians familiarities, and their long presence in the market. Among the anti-TNFs, etanercept and adalimumab were holding around 50% of the total in the 7MM market share in 2017.

Among the currently approved advanced classes, the growth of anti-TNF, T cell inhibitor, and B cell Inhibitor are expected to be relatively flat mainly due to the entry of biosimilars which ultimately leads to erosion of sales value.

As per DelveInsight's analysts the JAK inhibitor class expected to grow with a significant CAGR during the forecast period owing to market penetration of already approved products, entry and adoption of emerging drugs, and increase in physicians familiarities, and placing of JAK as a treatment option in the first line.

The Biosimilars started entering the United States and EU (i.e. Remicade biosimilars) and due to this sales value has started declining and the impact will be more pronounced when biosimilars/ generics of some blockbuster drugs like Humira (i.e. 2023 in the US), Xeljanz (i.e. 2025 in the US) will going to hit into the market and this will impact the growth of RA market significantly.

Among the recently launched and upcoming therapies, upadacitinib and filgotinib have the potential to impact the market owing to more selective oral JAK1 inhibitors and better clinical profile compared to already approved JAKi. Although upadacitinib will have a slight edge over filgotinib owing to order of entry, slightly better efficacy data, and recent FDA rejection of filgotinib.

To know how the trends will be impacting the market, click on the link to download the sample: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market

Story continues

Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory autoimmune disease and is characterized by chronic pain and joint destruction that usually progress from distal to more proximal joints. Even after years of research, the cause of rheumatoid arthritis is still unknown. Rheumatoid Arthritis symptoms include joint pain, stiffness, swelling, and decreased movement of the joints. Rheumatoid arthritis diagnosis is done by a combination of patient's symptoms, results of doctor's examination, assessment of risk factors, family history, a joint assessment by ultrasound sonography, and assessment of laboratory markers such as elevated levels of CRP and ESR in serum and detection of Rheumatoid Arthritis -specific autoantibodies. Rheumatoid Arthritis has a predilection to affect women, that's why the incidence and prevalence rates in women for RA is 2- 3 times more as compared to men. The total prevalent cases of Rheumatoid Arthritis in the 7MM were observed to be 4,356,793 in 2017 which are estimated to rise during the study period (20172030). The United States accounted for the highest number of cases in the 7MM.

The report provides an in-depth historical and forecasted analysis of Rheumatoid Arthritis Epidemiology segmented by:

Total Prevalent Cases

Total Diagnosed Prevalent Cases

Gender-specific Prevalent Cases

Age-specific Prevalent Cases

Severity-specific Prevalent Cases

Patients on targeted therapies

Line-Wise Treated Cases

Rheumatoid Arthritis Treatment Market

The Rheumatoid Arthritis treatment paradigm includes medicine, supportive treatment and surgery. Currently, there are three primary treatment options for severe and advancing Rheumatoid Arthritis which include DMARDs, NSAIDs, and corticosteroids. Rheumatoid market consists of many different drug target agents forming different drug classes. Conventional DMARDs are a group of drugs (i.e. methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) that have been shown to affect the underlying cause of RA by damping down over-activity of the immune system, which helps to ease pain, swelling and stiffness, and prevent changes occurring within the joint. Among csDMARDS, methotrexate (MTX) is considered as a part of the first treatment strategy. MTX remains the anchor drug in RA; along with usage as monotherapy, it is also the basis for combination therapies, either with GC or with other csDMARDs, bDMARDs or tsDMARDs.Patients refractory to csDMARDS or with severe symptoms usually treated with a wide variety of biologics DMARDs classes like anti-TNF, T cell inhibitor, B cell Inhibitor, Interleukin Inhibitors and targeted synthetic DMARDs like JAK Inhibitors. The drug classes include blockbusters Anti-TNF (Etanercept, Infliximab, Adalimumab, Certolizumab-pegol) JAK inhibitors (tofa citinib, baricitinib, upadacitinib, Peficitinob) B-cell inhibitors (Rituximab), Interleukin Inhibitors (Tocilizumab, Sarilumab), T-cell inhibitors (Abatacept), DMARDs, other novel inhibitors, etc.

Biological DMARDs showed promising results in treating RA patients and market penetration is expected to be more in the future and this class is expected to drive the growth of the market. Oral classes such as JAKi and upcoming BTKi due to patient convenient RoA are also expected to contribute to the Rheumatoid Arthritis market growth. The market for Rheumatoid Arthritis possesses fierce competition but still, there is a high demand for new therapies having similar or better efficacy, however, improved safety profile as well as patient adherence. Because of high competition, the new entrants are expected to be met with some resistance and will experience slow uptake, as the market is currently dominated by the anti-TNFs and entry of biosimilars will further pose significant challenges to new and upcoming treatment. It goes without saying that the dynamics of the Rheumatoid Arthritis market is expected to change because of the launch of emerging therapies, companies like GlaxoSmithKline [Otilimab (MOR103/GSK3196165)], Taisho Pharmaceutical [Ozoralizumab (TS-152)], Gilead and Galapagos NV [Filgotinib (GS-6034; Jyseleca)], and R-Pharm (Olokizumab) with their key candidates are in registrational or late clinical-stage. In addition to this, companies like Merck KGaA (Evobrutinib), Pfizer (PF-06650833, and PF-06651600), Roche (Fenebrutinib), and several others in phase II clinical development stage with their investigational candidates.

As many potential therapies are being investigated for the management of Rheumatoid Arthritis, it is for sure that the treatment space will experience a significant impact during the forecast period of 20202030.

As the emerging drugs will be entering the market, to know what will be their impact on the existing market, which drug will be a blockbuster, and for which line of treatment these drugs will be used? Download the RA Report to know more:- https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market

Scope of the Report

Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.

Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).

Markets Segmentation: By Geographies, By Therapies (Forecasted + Historical).

Companies Covered: GlaxoSmithKline, Gilead, Galapagos NV, R-Pharm, Taisho Pharmaceuticals, Aclaris Therapeutics, Viela Bio, Bristol Myers Squibb, AbbVie, Pfizer, Philogen, Akros Pharma, Japan Tobacco, Merck KGaA, Genentech, Mesoblast, UCB Pharma, PRA HEALTH SCIENCES, Izana Bioscience, Takeda, Abivax S.A, Hope Biosciences, Genosco (Oscotec) and several others.

Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis

Market trends, pipeline analysis across different stages of development (Phase III and Phase II), and market size by therapies.

Tools used such as SWOT analysis, Porter's Five Forces, PESTLE analysis, BCG Matrix analysis methods.

Case Studies

KOL's Views

Analyst's View

Table of Contents

1. Key Insights

2. Executive Summary of Rheumatoid Arthritis

3. SWOT Analysis of Rheumatoid Arthritis

4. Rheumatoid Arthritis Market Share (%) Distribution Overview at a Glance: By Country

5. Rheumatoid Arthritis Market Share (%) Distribution Overview at a Glance: By Class

6. Rheumatoid Arthritis Disease Background and Overview

7. Rheumatoid Arthritis Epidemiology and Patient Population

8. Rheumatoid Arthritis Epidemiology Scenario: 7MM

9. The United States Rheumatoid Arthritis Epidemiology

10. EU-5 Rheumatoid Arthritis Epidemiology

10.1. Germany

10.2. France

10.3. Italy

10.4. Spain

10.5. The United Kingdom

11. Japan Rheumatoid Arthritis Epidemiology

12. Current Rheumatoid Arthritis Treatment Practices

12.1. Medications

12.2. Supportive Treatment

12.3. Surgery

12.4. Treatment Algorithm

12.5. Guideline of Rheumatoid Arthritis

13. Unmet Needs

14. Patient Journey of Rheumatoid Arthritis

15. Key Endpoints in Rheumatoid Arthritis Clinical Trials

16. Rheumatoid Arthritis Marketed Therapies

16.1. Marketed Therapies Key Cross

16.2. Olumiant (Barticinib): Eli Lilly and Company/Incyte Corporation

16.3. Rinvoq (Upadacitinib): AbbVie

16.4. Xeljanz (Tofacitinib): Pfizer/PV PRISM CV

16.5. Remicade (Infliximab): Janssen Biotech (Centocor)

16.6. Enbrel (Etanercept): Immunex/Amgen

16.7. Rituxan/MabThera (Rituximab): Genentech/Biogen

16.8. Certolizumab-pegol (Cimzia): UCB Inc.

16.9. Golimumab (Simponi): Janssen Biotech

16.10. Humira (adalimumab): AbbVie

16.11. Orencia (Abatacept): Bristol Myers Squibb

16.12. Smyraf (Peficitinib): Astella Pharma

16.13. Actemra (Tocilizumab): Roche

16.14. Kineret (Anakinra): Swedish Orphan Biovitrium (SOBI)

16.15. Kevzara (Sarilumab): Regeneron and Sanofi

17. Rheumatoid Arthritis Emerging Therapies

17.1. Key Cross

17.2. GSK3196165 (otilimab/MOR103): GlaxoSmithKline

17.3. Filgotinib (GS-6034; GLPG0634; Jyseleca): Gilead and Galapagos NV

17.4. Olokizumab: R-Pharm

17.5. TS-152 (Ozoralizumab): Taisho Pharmaceuticals

17.6. ATI-450 (CDD-450): Aclaris Therapeutics

17.7. VIB4920: Viela Bio

17.8. Branebrutinib: Bristol Myers Squibb

17.9. ABBV-3373 and ABBV-154: AbbVie

17.10. Dekavil (F8IL10): Pfizer/Philogen

17.11. PF-06651600 (Ritlecitinib): Pfizer

17.12. JTE 051: Akros Pharma/Japan Tobacco

17.13. Evobrutinib (M2951): Merck KGaA

17.14. PF-06650833: Pfizer

17.15. Fenebrutinib (GDC-0853, RG7845): Genentech (subsidiary of Roche)

17.16. MPC-300-IV (Allogeneic Mesenchymal Precursor Cells): Mesoblast

17.17. Bimekizumab: UCB Pharma/PRA HEALTH SCIENCES

17.18. Namilumab (IZN-101; AMG203): Izana Bioscience/Takeda

17.19. ABX464: Abivax S.A.

17.20. HB-AdMSCs: Hope Biosciences

17.21. SKI-O-703: Genosco (Oscotec)

18. Conjoint Analysis of Rheumatoid Arthritis

More here:
Rheumatoid Arthritis Market expected to increase with a decent CAGR of approx. 3% during the study period 2017-30 - Yahoo Finance

Anterior cruciate ligament, or ACL, injuries are one of the most common types of knee injury and occur particularly in athletes or people who exercise and play sport regularly. ACL injuries can be treated surgically or non-surgically, depending on the patient, but may lead to an increased risk of osteoarthritis in later life. A new study, published in October 2020 in Scientific Reports, suggests that production of a certain protein in the knee joint following ACL injury may indicate an increased risk of osteoarthritis in future, allowing clinicians to better predict and treat this condition at an earlier stage.

What is ACL injury?

The ACL is one of the ligaments in the knee, and helps to move the joint back and forward. It is most commonly injured during running or playing sport: injuries to the ACL are known as sprains or tears. They can range from being mild, where the ligament is just stretched, to severe, where it is completely torn in two.

Patients may become aware of their knee making a popping noise, suddenly giving way, being painful, swelling and/or not moving properly. ACL injury can usually be diagnosed on examination by a doctor, but imaging may be required to ascertain the severity of the injury.

Treatment of ACL injury

If the patient wishes to return to full mobility, ACL injuries tend to require surgery as the ligament cannot repair itself. This can usually be done via arthroscopy (commonly known as keyhole surgery), which is less invasive and has a quicker recovery time compared to open surgery. For some elderly or very inactive patients, who do not need to return to great knee mobility, surgery may not be required and they may be able to use a brace and/or have physiotherapy instead if the injury is not very severe.

ACL injury and osteoarthritis

Unfortunately, patients who suffer an ACL injury also have a higher risk of developing arthritis, and in particular osteoarthritis, in the knee as they grow older. Osteoarthritis, also known as wear-and-tear arthritis, is common in elderly people, and occurs when the surface of the joint wears away, causing pain, swelling and loss of mobility.

Osteoarthritis cannot be cured but can be treated and prevented from worsening through medications, lifestyle changes such as diet and exercise, and, in some cases, surgery.

The recent study in Scientific Reports has suggested that production of a specific protein that helps lubricate the knee joint may be a predictor of future arthritis in patients with ACL injury. The study was conducted on dogs that had suffered ACL injury but the protein, called lubricin, is present in healthy knee joints in all mammals, including humans. The results may therefore be useful in treating human patients as well, and further studies are taking place to confirm if this is the case.

The study found that levels of lubricin significantly increased in those dogs that had suffered an ACL tear, before any other signs of arthritis were detected. The researchers concluded that increased levels of this protein may therefore be a marker for predicting osteoarthritis earlier, thus allowing patients to seek treatment more promptly and to make the lifestyle changes that could prevent their osteoarthritis from deteriorating.

This study is an encouraging example of how research can aid the development of treatment for common injuries and prevent subsequent and damaging side-effects later on in life.

Read this article:
ACL injury and osteoarthritis: causes, symptoms and treatment - Lexology

CMI presents an in-depth overview of the Global Rheumatoid Arthritis Treatment Market Study, detailing the latest product/industry coverage and market forecasts and status by 2027. Market research is categorized as a key area to accelerate marketization. The current market is evolving its presence and some of the major players in the study are Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,

This study focuses on the Global Rheumatoid Arthritis Treatment Market status, future forecast, growth opportunity, key market, and emerging players. The study objectives are to present the Rheumatoid Arthritis Treatment growth in Key regions. In order to provide valuable insight into each key element of the market, the highest and slowest growing market segment in the study is described. Newmarket participants are emerging and are accelerating the transition in the antistatic market. Merger and acquisition activities are expected to change the market environment for this industry.

You Keep Your Social Distance And We Provide You A Social DISCOUNT Use QUARANTINEDAYS Code In Precise Requirement And Get FLAT $1,000 OFF On All CMI Reports.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/166

The Global Rheumatoid Arthritis Treatment is segmented by:

By Product Type: Global Rheumatoid Arthritis Treatment Market, By Application.

Regional Markets: United States, Europe, China, Japan, Southeast Asia, India & Central & South America

List of Companies Mentioned: Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,

1) Does Study provide Latest Impact on Market due to COVID & Slowdown?

Yes, the study has considered a chapter on Impact Analysis and this 2020 Edition of the report provides detailed analysis and its impact on growth trends and market sizing to better understand the current scenario.

2) How companies are selected or profiled in the report?

The list of some players that are profiled in the report includes Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,.. the list is sorted to come up with a sample size of at least 50 to 100 companies having greater topline value to get their segment revenue for market estimation.

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

3) Is it possible to narrow down business segments by Application of this study?

Yes, depending upon the data availability and feasibility check by our Research Analyst, a further breakdown in business segments by end-use application in relation to type can be provided (If applicable) by Revenue Size or Volume*.

4) What is the base year of the study? What time frame is covered in the report?

Furthermore, the years considered for the study are as follows:

Historical year 2014-2019

Base year 2019

Forecast period** 2020 to 2027 [** unless otherwise stated]

Use QUARANTINEDAYS Code In Precise Requirement And Get FLAT $1,000 OFF On This Reports

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/166

** We will also include opportunities to utilize in micro markets that stakeholders can invest in, a detailed analysis of key competitors, and key services. **

Global Rheumatoid Arthritis Treatment Market What to expect from this report:

Focused Study on Niche Strategy and Market Development & penetration Scenario

Top 10 Global Rheumatoid Arthritis Treatment Companies in Global Market Share Analysis: Leaders and Laggards in 2017, 2019

Gain strategic insights on competitor information to formulate effective R&D moves

Identify emerging players and create effective counter-strategies to outpace competitive edge

Identify important and diverse product types/services offering carried by major players for market development

And many more .

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: Global Rheumatoid Arthritis Treatment MarketLandscape

PART 06: Global Rheumatoid Arthritis TreatmentMarket Sizing

PART 07: Global Rheumatoid Arthritis TreatmentMarket Segmentation

PART 08: CUSTOMER LANDSCAPE

PART 10: DECISION FRAMEWORK

PART 09: REGIONAL LANDSCAPE

PART 11: MARKET DYNAMICS: DRIVERS, TRENDS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/166

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

**Be Safe and Stay Home**

Visit link:
Rheumatoid Arthritis Treatment Market Opportunity and Business Industry By Forecast to 2026 | Coherent Market Insights.com - re:Jerusalem

A new report by XploreMR takes a deep dive into the Rheumatoid Arthritis Diagnosis Tests Market after conducting meticulous research, assessing each microscopic aspect of the market. The researches have connected the dots with minuscule details that shape into an intricate, immaculate yet elucidate study. The report presents a thoroughly scrutinized study of the Rheumatoid Arthritis Diagnosis Tests Market, leaving no stone unturned in offering market players a valuable and constructive tool that navigates them in the profitable path with the right set of objectives.

Following the methodology of Porters Five Forces analysis, the report emphasizes macro concepts such as the threat of new entries in the Rheumatoid Arthritis Diagnosis Tests Market, supplier power, threat of substitution, and buying power. Dwelling deeper into each of the factors, details about the competitive landscape, strategies of leading market players, and changes in the landscape, are also analyzed. In addition to competitive analysis, the researchers have also employed PESTEL analysis to study the impact of political, economic, social, technological, environmental, and legal factors on the keyword, thus leaving no loose ends.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/336

The researchers have studied the factors that are expected to drive the growth of the Rheumatoid Arthritis Diagnosis Tests by creating revenue opportunities, directly and indirectly. Similarly, the emerging trends, both long-term and short-term, present factors that are likely to impact the markets growth and project the direction the whole market is moving. Economical, technological, or any other trend that could bestow opportunities, have been studied. Moreover, the researchers have expanded the analysis beyond growth prospects and analyzed the possible restraining factors to the growth of the Rheumatoid Arthritis Diagnosis Tests Market, thus enabling market players to foresee the likely challenges and emerge successful through the forecast period 2017 2025.

In addition to the macro-economic factors that drive the global market, the market divulges micro-economic factors, diving into each individual segment such as geographical, end-use segments, and products, among others, and studies each of the segments with respect to different geographies. The geography-specific insights paint a crystal clear picture of the growth of every individual segment studied in the report, thereby enabling regional market players to leverage the trends in the region.

The report assesses key players in the Rheumatoid Arthritis Diagnosis Tests Market, studying their services, strategies, landmarks, growth plans, and recent developments. By studying multiple organizations covering small, medium, and large players the report enables emerging players to equip themselves with knowledge of competition scenarios. The most critical aspect in the competitive landscape individual growth strategy is studied extensively by dwelling into the foregoing growth trajectory of the organization. Moreover, the study paints a picture of the individual standpoints of the players in the years to come, considering the drivers and trends.

To breakdown the vast study that spreads through geographies, products, and end-use segments, among other market-specific segments, the authors present CAGR (Compound Annual Growth Rate) of each segment throughout the years of forecast. CAGR is a simplistic representation of growth that clearly projects which segment registered the highest/least growth through the forecast period 2017 2025. Moreover, each segment is analyzed on the basis of volume and volume, also projected with year-on-year growth and CAGR.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/336

Researchers also present production and consumption analysis, key findings, important suggestions and recommendations, and other aspects, thus offering a comprehensive picture of the Rheumatoid Arthritis Diagnosis Tests Market to bolster market players in planning their strategies in the years to come.

Important Questions Answered

Highlights of TOC:

Overview: Presents a broad overview of the Rheumatoid Arthritis Diagnosis Tests market, acting as a snapshot of the elaborate study that follows.

Market Dynamics: A straight-forward discussion about key drivers, restraints, challenges, trends, and opportunities of the Rheumatoid Arthritis Diagnosis Tests market.

Product Segments: Explores the market growth of the wide variety of products offered by organizations, and how they fare with end-users.

Application Segments: This section studies the key end-use applications that contribute to the market growth and the emerging opportunities to the Rheumatoid Arthritis Diagnosis Tests market.

Geographical Segments: Each regional market with a region-specific study of each segment- is carefully assessed for understanding its current and future growth scenarios.

Company Profiles: Leading and emerging players of the Rheumatoid Arthritis Diagnosis Tests Market are thoroughly profiled in the report based on their market share, market served, products, applications, regional growth, and other factors.

Get Full Report Access athttps://www.xploremr.com/cart/336/SL

Why Do Companies Trust XMR?

About Us

XploreMR, a leading market research firm, headquartered in San Jose, USA, XploreMR has, in a short span of time, served the market research needs of some of the biggest Fortune 500 companies. XploreMR also has highly personalized market research offerings for SMEs, and we pride ourselves on being uniquely positioned to have worked with colossal multinational firms and small, boutique firms. Our experience of working with such a diverse set from all over the world has given us invaluable perspectives on objectives, outlooks, goals, and eventually, the collective, symbiotic growth that stakeholders across the value chain aspire for. We keep these perspectives and aspirations in mind every time we work on a project, and this motivates us to exceed client expectations on a consistent basis

Contact us:

XploreMR

111 North Market Street, Suite 300,

San Jose, CA 95113, United States

Ph.No: +16692840108

E-mail id- [emailprotected]

Web: https://xploremr.com

See the original post here:
Rheumatoid Arthritis Diagnosis Tests Market Projection By Top key Players, Share, Size, Demand, Opportunities, Sale Area, Revenue Analysis Forecast To...